Tumor-related leucocytosis and chemotherapy-induced neutropenia: Linked or independent prognostic factors for advanced non-small cell lung cancer?

Lung Cancer

Volumn 66, Issue 1, 2009, Pages 8-14

  Maione, Paolo ^a   Rossi, Antonio ^a   Di Maio, Massimo ^b   Gridelli, Cesare ^a  

^a S G MOSCATI HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chemotherapy induced neutropenia; NSCLC; Tumor related leucocytosis

Indexed keywords

CISPLATIN; COLONY STIMULATING FACTOR 1; DOCETAXEL; DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MELPHALAN; NAVELBINE; PARATHYROID HORMONE RELATED PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADVANCED CANCER; BLOOD TOXICITY; BONE MARROW TOXICITY; BREAST CANCER; CANCER RELAPSE; CLINICAL TRIAL; CYTOKINE PRODUCTION; GRANULOCYTOSIS; HUMAN; HYPERCALCEMIA; LARGE CELL CARCINOMA; LEUKOCYTE COUNT; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL TIME; THROMBOCYTOSIS; TUMOR RELATED LEUKOCYTOSIS;

AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LEUKOCYTE COUNT; LEUKOCYTOSIS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; PROGNOSIS; RISK FACTORS;

EID: 69249241735     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.02.022     Document Type: Review

References (52)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics. CA Cancer J Clin 57 (2007) 43-66
2. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
3. Delbaldo C., Michiels S., Syz N., Soria J.C., Le Chevalier T., and Pignon J.P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 292 (2004) 470-484
4. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
5. Brundage M.D., Davies D., and Mackillop W.J. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122 (2002) 1037-1057
6. Efficace F., Bottomley A., Smit E.F., Lianes P., Legrand C., Debruyne C., et al. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 17 (2006) 1698-1704
7. Sequist L.V., Joshi V.A., Janne P.A., Muzikansky A., Fidias P., Meyerson M., et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 12 (2007) 90-98
8. Mandrekar S.J., Schild S.E., Hillman S.L., Allen K.L., Marks R.S., Mailliard J.A., et al. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer 15 (2006) 781-792
9. Di Maio M., Gridelli C., Gallo C., Shepherd F., Piantedosi F.V., Cigolari S., et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 6 (2005) 669-677
10. Pallis A.G., Agelaki S., Kakolyris S., Kotsakis A., Kalykaki A., Vardakis N., et al. Hellenic Oncology Research Group (HORG). Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. Lung Cancer (2008) 10.1016/j.lung can.2008.03.030
11. Thomson S.P., Kessler J.F., and Miller T.P. Leukocyte concentrations in discrimination of benign from malignant lung lesions. Am J Med 80 (1986) 1035-1040
12. Slungaard A., Ascensao J., Zanjani E., and Jacob H.S. Pulmonary carcinoma with eosinophilia. New Engl J Med 309 (1983) 778-781
13. Ascensao J.L., Oken M.M., Ewing S.L., Goldberg R.J., and Kaplan M.E. Leucocytosis and large cell lung cancer. A frequent association. Cancer 60 (1987) 903-905
14. Asano S., Urabe A., Okabe T., Sato N., Kondo Y., Ueyama Y., et al. Demonstartion of granulopoietic factors in the plasma of nude mice transplanted with a human lung cancer and in the tumor tissue. Blood 49 (1977) 845-852
15. Anger B., Bockman R., Andreeff M., Erlandson R., Jhanwar S., Kameya, et al. Characterization of two newly established human cell lines from patients with large-cell anaplastic lung carcinoma. Cancer 50 (1982) 1518-1529
16. Baldwin G.C., Gasson J.C., Kaufman S.G., Quan S.G., Williams R.E., Avalos B.R., et al. Nonhematopoietic tumor cells express functional GM-CSF receptors. Blood 73 (1989) 1033-1037
17. Okabe T., Fujisawa M., Kudo H., Honma H., Ohsawa N., and Takaku F. Establishment of a human colony-stimulating-factor-producing cell line from an undifferentiated large cell caricnoam of the lung. Cancer 54 (1984) 1024-1029
18. Katoh Y., Nakamura M., Ohnishi Y., Shimamura K., Ueyama Y., and Tamaoki N. Autonomous production of granulocyte.colony stimulating factor in tumor xenografts associate dwith leucocytosis. Br J Cancer 68 (1993) 715-719
19. Inoue M., Minami M., Fujii Y., Matsuda H., Shirakura R., and Kido T. Granulocyte colony-stimulating factor and interleukin-6-producing lung cancer cell line, LCAM. J Surg Oncol 64 (1997) 347-350
20. Suda T., Miura Y., mizoguchi H., Kubota K., and Takaku F. A case of lung cancer associated with granulocytosis and production of colony-stimulating activity by the tumour. Br J Cancer 41 (1980) 980-984
21. Shijubo N., Inoue Y., Hirasawa M., igarashi T., Mori M., Matsutura A., et al. Granulocyte colony-stimulating factor-producing large cell undifferentiated caricnomaof the lung. Intern Med 31 (1992) 277-280
22. Sawyers C.L., Golde D.W., Quan S., and Nimer S.D. Production of granulocyte-macrophage colony-stimulating factor in two patients with lung cancer, lekocytosis, and eosinophilia. Cancer 69 (1992) 1342-1346
23. Matsuguchi T., Okamura S., Kawasaki C., Shimoda K., Omori F., Hayashi S., et al. Constitutive production of granulocyte colony-stimulating factor and interleukin-6 by a human lung cancer cell line, KSNY: gene amplificationj and increased mRNA stability. Eur J Haematol 47 (1991) 128-133
24. Oshika Y., Nakamura M., Hatanaka H., Abe Y., Tokunaga T., Ohnishi Y., et al. A human lung cancer xenograft producing granulocyte-colony stimulating factor and parathyroid hormone-related protein. Oncol Rep 5 (1998) 359-362
25. Furihata M., Sonobe H., Iwata J., Ido E., Ohtsuki Y., Asahi Y., et al. Lung squamous cell carcinoma producing both parathyroid hormone-related peptide and granulocyte colony stimulating factor. Pathol Int 46 (1996) 376-379
26. Kimura H., Yamaguchi Y., Sun L., Iwagami S., and Sugita K. Establishment of large cell lung cancer cell lines secreting hematopoietic factors inducing leukocytosis and thrombocytosis. Jpn J Clin Oncol 22 (1992) 313-319
27. Nakamura K., Takahashi T., Tsuyuoka R., Ueda Y., Suzuki A., Okuno Y., et al. Identification of colony-stimulating factor activity in patients with malignant tumors associated with excessive leukocytosis. Jpn J Clin Oncol 21 (1991) 395-399
28. Kasuga I., Makino S., Kiyokawa H., Katoh H., Ebihara Y., and Ohyashiki K. Tumor-related lekocytosis is linked with poor prognosis in patiens with lung carcinoma. Cancer 92 (2001) 2399-2405
29. Albain K.S., Crowley J.J., LeBlanc M., et al. Survival determinants in extensive stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9 (1991) 1618-1626
30. Takigawa N., Segawa Y., Okahara M., et al. Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 15 (1996) 67-77
31. Watine J. Further comments on "A practical prognostic index for inoperable non-small-cell lung cancer": a clinical biologist's point of view. J Cancer Res Clin Oncol 124 (1998) 581-583
32. Wigren T. Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer. Radiother Oncol 44 (1997) 9-15
33. Paesman M., Sculier J.P., Libert P., et al. Prognostic factors for survival in advanced non-small lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. J Clin Oncol 13 (1995) 1221-1230
34. Ferrigno D., and Buccheri G. Hematologic counts and clinical correlates in 1201 newly diagnosed lung cancer patients. Monaldi Arch Chest Dis 59 (2003) 193-198
35. Kaminska J., Kowalska M., Kotowicz B., Fuksiewicz M., Wojcik E., Chachlinska M., et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clnicopathological features and prognosis. M-CSF-an independent prognostic factors. Oncology 70 (2006) 115-125
36. Kvinnsland S. The leucocyte nadir, a predictor of chemotherapy efficacy?. Br J Cancer 80 (1999) 1681
37. Gurney H. How to calculate the dose of chemotherapy. Br J Cancer 86 (2002) 1297-1302
38. Saarto T., Blomqvist C., Rissanen P., and Elomaa I. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75 (1997) 301-305
39. Poikonen P., Saarto T., Lundin J., Joensuu H., and Blomqvist C. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 80 (1999) 1763-1766
40. Mayers C., Panzarella T., and Tannock I.F. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 91 (2001) 2246-2257
41. Cameron D.A., Massie C., Kerr G., and Leonard R.C.F. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 89 (2003) 1837-1842
42. The Elderly Lung cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non small cell lung cancer. J Natl Cancer Inst 91 (1999) 66-72
43. Gridelli C., Perrone F., Gallo C., Cigolari S., Rossi A., Piantedosi F., et al. For the MILES Investigators. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95 (2003) 362-372
44. Gridelli C., Gallo C., Shepherd F.A., Illiano A., Piantedosi F., Robbiati S.F., et al. Gemcitabine plus vinorelbine compared to cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer. A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada - Clinical Trials Group. J Clin Oncol 21 (2003) 3025-3034
45. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995) 899-909
46. Cortes E.P., Holland J.F., Wang J.J., Sinks L.F., Blom J., Senn H., et al. Amputation and adriamycin in primary osteosarcoma. N Engl J Med 221 (1974) 998-1000
47. Carpenter J.T., Maddox W.A., Laws H.L., Wirtschafter D.D., and Soong S.J. Favorable factors in the adjuvant therapy of breast cancer. Cancer 50 (1982) 18-23
48. Singh S., Parulekar W., Murray N., Feld R., Evans W.K., Tu D., et al. Influence of gender on toxicity and treatment outcome in small cell lung cancer. J Clin Oncol 23 (2005) 850-856
49. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 14 (1996) 2590-2611
50. Ratain M.J. Body-surface area as a basis for dosing anticancer agents: science, myth, or habit?. J Clin Oncol 16 (1998) 2297-2298
51. Sawyer M., and Ratain M.J. Body surface area as a determinant of pharmacokinetics and drug dosing. Investigational New Drugs 19 (2001) 171-177
52. Bergh J. Tailored chemotherapy to equal toxicity: is it possible?. Recent Results Cancer Res 152 (1998) 328-340